Agenus reports 72% of patients had no cancer remaining at surgery after six weeks of BOT+BAL
AGEN•Agenus reported that 72% of patients with locally advanced dMMR colon cancer had no cancer remaining at surgery after six weeks of BOT+BAL in its Phase 2 NeoASIS study.
1. Phase 2 results
Agenus reported that 72% of patients with locally advanced dMMR colon cancer had no cancer remaining at surgery following six weeks of BOT+BAL in the Phase 2 NeoASIS study.
